



Mouse anti-PAX-8

Cat. No.: MSK107-05 (0.5 ml Concentrate); MSG107 (6 ml Ready-to-use)

Instructions for use

Intended use

This antibody is designed for the specific localisation of PAX-8 in formalin-fixed, paraffin-embedded tissue sections. Anti-PAX-8 antibody is intended for in vitro diagnostic use.

Specifications

Specificity: Human PAX-8

Clone: BC12

Isotype: Mouse IgG1

Species reactivity: Human +, others not tested

Summary and Description

PAX-8 belongs to the protein family of paired box transcription factors (Paired box protein PAX-8). PAX-8 is a sensitive marker for a variety of tumours especially for carcinomas of the ovary, kidney and the thyroid. PAX-8 is expressed both in primary tumours and metastasis. In contrast to polyclonal PAX-8 antibodies, the mouse monoclonal PAX-8 antibody, clone BC12, has been shown to recognize PAX-8 and not PAX2, PAX5 or PAX6 proteins. Therefore PAX-8 (BC12) does not stain B-cells, nor does it recognize epitopes of pancreatic origin and neuroendocrine cells in stomach and colon. Several studies describe the superiority of the monoclonal PAX-8 to commercially available polyclonal PAX-8 antibodies in the diagnosis of thyroid and renal carcinomas.

Reagent provided

Mouse monoclonal antibody in buffer with carrier protein and preservative for stabilisation in the following formats:

Concentrate: 0.5 ml (Cat. No. MSK107-05) **Ready-to-use:** 6 ml (Cat. No. MSG107)

Dilution of primary antibody

Dilution of Zytomed Systems' concentrated antibody depends on the detection system used. The final working dilution must always be determined by the user. The elaboration of staining protocol should be done by an experienced specialist. For Zytomed Systems' recommendations see chapter 'Staining procedure'.

Storage and handling

The antibody should be stored at 2-8°C without further dilution. Dilutions of the concentrated antibody should be done with a suitable antibody dilution buffer (e.g. ZUC025 from Zytomed Systems). The diluted antibody should be stored at 2-8°C after use. Stability of this working solution depends on various parameters and has to be confirmed by appropriate controls. The antibody provided is suitable for use until the expiry date indicated on the label, if stored at 2-8°C. Do not use product after the expiry date. Positive and negative controls should be run simultaneously with all specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the antibody is suspected, contact Zytomed Systems' technical support or your local distributor.

Precautions

Use through qualified personnel only.

Wear protective clothing to avoid contact of reagents and specimens with eye, skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with large amounts of water. Microbial contamination of the reagent must be avoided, since otherwise non-specific staining may occur. Sodium azide (NaN₃), used for stabilisation, is not considered hazardous material in the concentration used. Reaction of sodium azide with lead or copper in drainage pipes can result in the formation of highly explosive metallic azides. Sodium azide should be discarded in a large volume of running water to avoid formation of deposits. Material safety data sheets (MSDS) are available upon request.

Date of approval: 2023-06-30 Revision: V01 Page 1 of 2

Staining procedure

Refer to the following table for conditions specifically recommended for this antibody. Also refer to detection system data sheets for guidance on specific staining protocols or other requirements.

Parameters Zytomed Systems recommendations

*Pre-treatment Heat Induced Epitope Retrieval (for example in citrate buffer pH 6.0)

*Control tissue Kidney, renal cell carcinoma, ovarian serous carcinoma

*Working dilution 1:50 (for concentrates)

*Incubation time 60 minutes

Quality control

The recommended positive control tissues for this antibody are kidney, renal cell carcinoma, and ovarian serous carcinoma. We recommend carrying out a positive and a negative control with every staining run. Please refer to the instructions of the detection system for guidance on general guality control procedures.

Troubleshooting

If you observe unusual staining or other deviations from the expected results please read these instructions carefully, refer to the instructions of the detection system for relevant information or contact your local distributor.

Expected results

This antibody stains positive in nuclei in formalin-fixed, paraffin-embedded tissue sections. Further details about the expression pattern of PAX-8 can be found in the chapter 'Summary and Description'. Interpretation of the staining results is solely the responsibility of the user. Any experimental result should be confirmed by a medically established diagnostic procedure.

Limitations of the Procedure

Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining, for example variations in fixation and embedding or the inherent nature of the tissue can cause inconsistent results (Nadji and Morales, 1983). Endogenous peroxidase, pseudoperoxidase activity in erythrocytes or biotin may cause non-specific staining depending on the detection system used. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive results with HRP (horse radish peroxidase) detection systems (Omata et al, 1980). Inadequate counterstaining and mounting can influence the interpretation of the results.

Zytomed Systems warrants that the product will meet all requirements described from its shipping date until the expiry date is reached, if the product is stored and utilised as recommended. No additional guarantees can be given. Under no circumstances shall Zytomed System be liable for any damages arising out of the use of the reagent provided.

Performance characteristics

Zytomed Systems has conducted studies to evaluate the performance of the antibody for use with a standard detection system. The product has been found to be sensitive and specific to the antigen of interest with minimal or no cross-reactivity.

Bibliography

Nadji M and Morales AR. Ann N.Y. Acad Sci 1983; 420:134-139 Nonaka D et al. Am J Surg Pathol 32:1566-1571, 2008 Ozcan A et al. Arch Pathol Lab Med 136:1541-1551, 2012 Moretti L et al. Mod Pathol 25:231-236, 2011 Tacha D et al. Appl Immunohistochem Mol Morphol 21:59-63, 2013 Omata M et al. Am J Clin Pathol 1980; 73: 626-632 Laury AR et al. Am J Surg Pathol 35:816-826, 2011 Lotan TL. Am J Surg Pathol 33:1037-1041, 2009 Hu Y et al. J Clin Pathol 65:254-256, 2012 Toriyama A et al. Histopathol 65:465-472, 2014



 $www.zytomed\hbox{-}systems.de$

Zytomed Systems GmbH • Anhaltinerstraße 16 • 14163 Berlin, Germany • Tel: (+49) 30-804 984 990

Explanations of the symbols on the product label

Symbols are used in accordance with ISO 15223-1. Further symbols on the product label might be:



GSH07: Warning / Attention

RUO For Research Use Only

Date of approval: 2023-06-30 Revision: V01 Page 2 of 2